Skip to main content

Biogen QALSODY revenue

  • BIIB · Nasdaq
  • Biotechnology
  • S&P 500
$253.40+1.17%Close 13 Nov 2026 · Market value $37.59B

QALSODY revenue at Biogen came to $37.5M for the quarter to 30 Sep 2026, up 42.0% from a year earlier.

As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.

By quarter

$1.7MSep 2023$4.6MMar 2024$5.0MJun 2024$11.1MSep 2024$11.7MDec 2024$15.5MMar 2025$20.0MJun 2025$26.4MSep 2025$25.0MDec 2025$32.5MMar 2026$31.9MJun 2026$37.5MSep 2026
Biogen QALSODY revenue, every reported period
Period endingQALSODY revenueChange on a yearFiled
30 Sep 2026$37.5Mup 42.0%28 Oct 2026
30 Jun 2026$31.9Mup 59.5%29 Jul 2026
31 Mar 2026$32.5Mup 109.7%29 Apr 2026
31 Dec 2025$25.0Mup 113.7%6 Feb 2026
30 Sep 2025$26.4Mup 137.8%30 Oct 2025
30 Jun 2025$20.0Mup 300.0%31 Jul 2025
31 Mar 2025$15.5Mup 237.0%1 May 2025
31 Dec 2024$11.7M—12 Feb 2025
30 Sep 2024$11.1Mup 552.9%30 Oct 2024
30 Jun 2024$5.0M—1 Aug 2024
31 Mar 2024$4.6M—24 Apr 2024
30 Sep 2023$1.7M—8 Nov 2023
31 Mar 2023$0—25 Apr 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · TYSABRI revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · financial statements

Every KPI and segment of BIIB, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.